---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-283719"
form_type: "8-K"
ticker: "PHAT"
cik: "0001783183"
company_name: "Phathom Pharmaceuticals, Inc."
filed_at: "2023-11-28T23:59:59+00:00"
generated_at: "2026-06-07T21:06:04.581242+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Phathom launches VOQUEZNA for erosive GERD; H. pylori regimens expected mid-Dec.

## Summary
- VOQUEZNA (vonoprazan) now available in 30-count bottles for erosive GERD treatment and heartburn relief.
- Phase 3 trial: 93% healing rate at Week 8 with VOQUEZNA 20mg vs 85% for lansoprazole 30mg.
- VOQUEZNA 10mg superior to lansoprazole 15mg at maintaining healing at 6 months (79% vs 72%).
- No mealtime dosing required; prescriptions fillable at major retail pharmacies and via BlinkRx.
- VOQUEZNA TRIPLE PAK and DUAL PAK for H. pylori expected commercially by mid-December 2023.

## SEC filing metadata
- accession: 0001193125-23-283719
- form_type: 8-K
- ticker: PHAT
- cik: 0001783183
- company_name: Phathom Pharmaceuticals, Inc.
- filed_at: 2023-11-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783183/000119312523283719/0001193125-23-283719-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783183/000119312523283719/d573061d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-283719
- JSON: https://secwatch.observer/filing/0001193125-23-283719.json
- Plain text: https://secwatch.observer/filing/0001193125-23-283719.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.